Asian flu study a MARVEL
Monday, 17 November, 2008
Phase III trials of Biota’s neuraminidase inhibitor CS-8958 for influenza are set to begin in several centres throughout Asia.
CS-8958, which was discovered by Japanese pharma Daiichi Sankyo and is co-owned by Biota, is a long-acting neuraminidase inhibitor (LANI) that early trials suggest is effective against influenza A and B as well as the H5N1 bird flu virus.
It is hoped that a single inhaled dose will be efficacious for treatment of flu and another once a week for prophylaxis.
The Phase III trial, nicknamed MARVEL, will be conducted in multiple centres in Japan, Taiwan, Hong Kong and Korea, in time for the Asian flu season. As well as the Phase III trial in adults, a Phase II/III study will be conducted in Japan for paediatric indications.
The duration of the trial will depend on the availability of patients and the extent of the flu season, Biota said in a statement.
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
Existing medicines could help treat deadly childhood dementia
Australian researchers have identified several existing TGA‑approved medicines that could help...
Statins reduce heart attack and stroke risk in older people
It has previously been unclear whether statins were effective in reducing heart attack and stroke...
